To: 5.1.2e 5.1.2e 5.1.2e @rivm.nl]; 5.1.2e 5.1.2e 5.1.2e 5.1.2e

From: 5.1.2e 5.1.2e

Sent: Mon 3/29/2021 3:26:07 PM

Subject: RE: Overview VE one dose and AZ 4 weeks in stead of 12 weeks

Received: Mon 3/29/2021 3:26:08 PM

GR VE overview 29Mar2021.pdf GR VE overview 29Mar2021.docx

Lumley 12Mar2021. MedRxiv. Pfizer & AZ. UK. Prospective cohort..pdf

Hi 5.1.2e

Please find attached the update of overall table of for the Health Council. In table 2, I also added the VE after 1 dose reported in the study by Shrotri. If you look at the VEs for the AZ vaccine 7-13, 14-20 and >=49 days after dose 1, it may not be very optimistic but for the days 28-34 and 35-48 days after dose 1 the VEs are more friendly (67 (95%CI 32-84) and 68 (95%CI 34-85) respectively). The time interval 7-13 and 14-20 days after dose 1 may be too early to capture an effect and >=49 days after dose 1 too long or the numbers too small. I still reported the VEs 7,13, 14-20 and >=49 days after dose 1 so it would fit in the description of the table.

I also stumbled upon a preprint of Lumley et al. in which they also report something about Ct values. I didn't read it in detail yet but maybe it contains some additional information for the presentation create by 5.1.2e

Best wishes,

To: 5.1.2e 5.1.2e < 5.1.2e @rivm.nl>; 5.1.2e 5.1.2e < 5.1.2e @rivm.nl>

Subject: Re: Overview VE one dose and AZ 4 weeks in stead of 12 weeks

Hi 5.1.2e

Here's my presentation draft. It may not include all available studies, but it should be enough to get the conversation with the Health Council started. There is one study that specifically aimed to look at VE against transmission (Shah et al.). I present this one first. The other three use Ct value as a proxy for viral load and thus a person's ability to transmit (higher Ct value = lower viral load). I threw this together quite quickly, so please let me know if you have questions or comments. It may be worthwhile to make this a living presentation to be updated with information as it becomes available.

A big thank you to 5.1.20 for helping me find these papers!

Best.

5.1.2e

5.1.2e 5.1.2e 5.1.2e

Centrum Infectieziektebestrijding | Centre for Infectious Disease Control Rijksinstituut voor Volksgezondheid en Milieu | National Institute for Public Health and the Environment

visitors: Antonie van Leeuwenhoeklaan 9 | 3721 MA Bilthoven | The Netherlands correspondence: Postbus 1 | 3720 BA Bilthoven | The Netherlands

5.1.2e

From: 5.1.2e 12 5.1.2e 5.1.2e Sent: Monday, 29 March 2021 13:27:17 To: 5.1.2e 5.1.2e 5.1.2e 5.1.2e Subject: RE: Overview VE one dose and AZ 4 weeks in stead of 12 weeks
Thanks a lot 5.1.2e
From: 5.1.2e 5.1.2e c 5.1.2e @rivm.nl> Sent: maandag 29 maart 2021 09:53 To: 5.1.2e 12e 5.1.2e 5.1.2e 5.1.2e
Hi 5.1.2e
Unfortunately, I don't yet have a draft of the presentation. I'll try to send you something today.
Best, 5.1.2e
From: 5.1.2e 12e 5.1.2e
Hi 5.1.2e
Tomorrow the health council will (start to) discuss the further the further vaccination strategy for which insight into transmission is relevant. Also they are asked to advice (again) on longer interval (for Pfizer) and for AZ the reverse (ie going from 12 weeks to 4 weeks). I understood that there will be also modelling work on these questions regarding interval.
On Wednesday we would discuss in the brainstorm session internally on transmission.
It would be very helpful if you could already share what is available.
 Could you update the overall table for the Health Council including info regarding one dose and interval? And if available on transmission? 5.1.20 Do you already have a draft presentation / info that I can get to prepare for the discussion tomorrow? Other relevant info?
Thanks a lot, regards, 5.1.2e